Nanobiotix/$NBTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Nanobiotix
Nanobiotix SA is a clinical-stage biotechnology company that has one operating segment, which focuses on developing product candidates that use its proprietary nanotechnology to transform cancer treatment by increasing the efficacy of radiotherapy. The company develops NanoXray products to help patients receiving radiotherapy by magnifying the effect of radiotherapy within tumor cells without increasing the dose to surrounding healthy tissues. Its product candidate is NBTXR3, a preclinical research program for cancer immunotherapies.
Ticker
$NBTX
Sector
Primary listing
Employees
108
Headquarters
Website
Nanobiotix Metrics
BasicAdvanced
$451M
-
-$1.70
1.58
-
Price and volume
Market cap
$451M
Beta
1.58
52-week high
$10.59
52-week low
$2.76
Average daily volume
13K
Financial strength
Current ratio
1.043
Quick ratio
0.977
Long term debt to equity
-69.977
Total debt to equity
-77.472
Interest coverage (TTM)
-8.44%
Profitability
EBITDA (TTM)
-79.693
Gross margin (TTM)
100.00%
Net profit margin (TTM)
947.59%
Operating margin (TTM)
949.35%
Effective tax rate (TTM)
-0.15%
Revenue per employee (TTM)
-$82,440
Management effectiveness
Return on assets (TTM)
-52.89%
Return on equity (TTM)
201.73%
Valuation
Price to revenue (TTM)
-52.02
Price to book
-5.74
Price to tangible book (TTM)
-5.74
Price to free cash flow (TTM)
-18.335
Free cash flow yield (TTM)
-5.45%
Free cash flow per share (TTM)
-0.508
Growth
Revenue change (TTM)
-119.86%
Earnings per share change (TTM)
33.47%
3-year revenue growth (CAGR)
39.53%
10-year revenue growth (CAGR)
10.01%
3-year earnings per share growth (CAGR)
2.08%
10-year earnings per share growth (CAGR)
6.86%
What the Analysts think about Nanobiotix
Analyst ratings (Buy, Hold, Sell) for Nanobiotix stock.
Bulls say / Bears say
Phase 1 re-irradiation data in locally advanced NSCLC showed a 12-month LPFS of 64% and OS of 83%, highlighting NBTXR3’s potential to improve outcomes in patients with limited options (GlobeNewswire)
First patient dosed in the Phase 2 CONVERGE trial for unresectable stage 3 NSCLC, advancing NBTXR3 into pivotal development and underscoring the company’s strategic progress (GlobeNewswire)
European health authorities reclassified JNJ-1900 from a medical device to a medicinal product, harmonizing global regulatory status and streamlining future approvals (GlobeNewswire)
Negative revenues of €7.2 million in 2024, compared to €36.2 million in 2023, due to a one-off non-cash liability from the NANORAY-312 study transfer, reflecting accounting headwinds for Nanobiotix (GlobeNewswire)
Net loss widened to €68.1 million in 2024, a 72% increase year-over-year, underscoring persistent unprofitability as clinical programs advance (Nasdaq)
Cash and cash equivalents declined to €39.8 million as of March 31, 2025, offering runway only into mid-2026 and raising potential financing risks if milestones are delayed (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 31 Aug 2025.
Nanobiotix Financial Performance
Revenues and expenses
Nanobiotix Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Nanobiotix stock?
Nanobiotix (NBTX) has a market cap of $451M as of September 17, 2025.
What is the P/E ratio for Nanobiotix stock?
The price to earnings (P/E) ratio for Nanobiotix (NBTX) stock is 0 as of September 17, 2025.
Does Nanobiotix stock pay dividends?
No, Nanobiotix (NBTX) stock does not pay dividends to its shareholders as of September 17, 2025.
When is the next Nanobiotix dividend payment date?
Nanobiotix (NBTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Nanobiotix?
Nanobiotix (NBTX) has a beta rating of 1.58. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.